Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | PRKACG | P22612 | 1/20 | 0.33 |
| ▸ | PRKACB | P22694 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330040 | 0.82 | AXL (0.46) | DGAT1 | |
| SCHEMBL11976878 | 0.78 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL1329995 | 0.77 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL31086380 | 0.77 | NPC1 (0.51) | NAMPTPRKACAPRKACGPRKACBROCK2 | |
| SCHEMBL14699328 | 0.77 | PRKACA (0.38) | DGAT1NAMPTPRKACAPRKACGPRKACB | |
| SCHEMBL28923118 | 0.77 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL1330995 | 0.75 | JAK2 (0.38) | DGAT1 | |
| SCHEMBL24809118 | 0.75 | DGAT1 (0.40) | DGAT1NAMPTMAPTALDH1A1 | |
| SCHEMBL31330571 | 0.74 | DGAT1 (0.53) | DGAT1MAPT | |
| SCHEMBL24159819 | 0.74 | DGAT1 (0.41) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569301-A1 | INDAZOLE INHIBITORS OF KINASE | Abbvie Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8293738-B2 | Indazole inhibitors of kinase | ABBOTT LABORATORIES (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011143430-A1 | INDAZOLE INHIBITORS OF KINASE | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | AURKA, AURKC, AURKB | DGAT1 3720/4885NAMPT 1497/4885PRKACA 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.